Exhibition showcases driving forces behind achieving global production of 100 million vehicles and thanks customers for their unwavering supportJourney begins with first model ‘Cortina Mark 2’ and the Pony, Hyundai Motor’s first independently developed modelThree iconic models ‒ SONATA, ELANTRA and Scoupe – highlight Hyundai’s drive to go ‘one step further’ in design, production and engineeringModern SUV and EV lineups reinforce Hyundai Motor’s transformation from traditional automaker to smart mobility solutions providerSEOUL, South Korea, Oct. 10, 2024 /PRNewswire/ — Hyundai Motor Company is marking its historic achievement of producing 100 million vehicles worldwide with the grand opening of its ‘One step further’ exhibition at Hyundai Motorstudio Seoul. The exhibition showcases the driving forces behind the 100-million-unit production milestone and conveys Hyundai’s gratitude to those customers who have been part of the journey.

This exhibition is a continuation of the 100 million production celebration held at Hyundai Motor’s Ulsan Plant on September 30. At that event, the company delivered the 100 million and first vehicle, an IONIQ 5, to its new owner, representing the brand’s gratitude to its customers for their unwavering support.
“It takes thousands of parts and pieces to build a car, with combined efforts of millions of people involved in R&D, design and manufacturing over many years,” said Sungwon Jee, Senior Vice President and Global Chief Marketing Officer at Hyundai Motor Company. “We wanted to shed light on these behind-the-scenes efforts that went into producing 100 million vehicles and tell the story of Hyundai Motor’s transformation from a traditional automaker to a leading smart mobility solutions provider.”
Spanning five floors, the exhibition begins on the first floor by introducing the Cortina Mark 2, Hyundai Motor’s first production model; and the Pony, Hyundai Motor’s first independently developed model. The exhibition continues on the second floor where the history of major Hyundai Motor plants is showcased.
The third floor highlights key drivers in achieving the 100 million production milestone, focusing on three iconic models: the first-generation SONATA, the first-generation ELANTRA and Scoupe.
The fourth and fifth floors feature the brand’s modern SUV lineup – SANTA FE, KONA and INSTER; and electric vehicle (EV) lineup – IONIQ 5, IONIQ 5 N and IONIQ 6, looking ahead to Hyundai Motor’s future as it moves forward from a traditional automaker to a smart mobility solutions provider.
Visit Hyundai Newsroom for more information
Photo – https://mma.prnewswire.com/media/2527469/Image_1__Hyundai_Celebrates_100_Million_Production_with__One_step_further__Exhibition.jpgPhoto – https://mma.prnewswire.com/media/2527470/Image_2__Hyundai_Celebrates_100_Million_Production_with__One_step_further__Exhibition.jpg

View original content:https://www.prnewswire.co.uk/news-releases/hyundai-motor-celebrates-production-milestone-of-100-million-vehicles-with-one-step-further-exhibition-302272283.html

ROCHESTER, N.Y., Oct. 9, 2024 /PRNewswire/ — CYRISMA, an all-in-one risk management platform, announced its Series A financing today. Led by Blueprint Equity, with participation from SaaS Venture and Golden Ventures, the funding will accelerate CYRISMA’s platform development, fuel customer success, and expand sales and marketing initiatives.

CYRISMA accelerates security programs for MSPs by providing a cost-effective, all-in-one solution to identify, prioritize, and remediate vulnerabilities, track compliance requirements, and manage AI security risk.
“In partnering with Blueprint Equity, we are excited to leverage their expertise and resources to further enhance our platform and support our customers,” said Liam Downward, co-founder and CPO of CYRISMA. “This investment will allow us to continue delivering an affordable and comprehensive risk management solution, empowering MSPs to protect their clients effectively. Additionally, it enables us to enter into new markets, expanding our reach and increasing brand awareness.”
Blueprint Equity’s Sheldon Lewis, who will join CYRISMA’s Board of Directors, commented, “With the rise of security threats for SMBs, there’s been an increasing number of businesses outsourcing their cybersecurity to MSPs. This has accelerated demand in the market for strong, multi-tenant cybersecurity solutions for MSPs to best serve their clients.” He added, “We were drawn to the breadth of the CYRISMA platform and their strong customer satisfaction. Oliver Downward, CEO, Liam, and the team have an unparalleled insight into the MSP market, and we’re honored to partner with CYRISMA during their next phase of growth.”
About CYRISMA
CYRISMA is an all-in-one risk management platform for Managed Service Providers. With the rise in security threats and demand for cybersecurity services, CYRISMA provides MSPs with an effective, all-in-one solution to manage their cybersecurity initiatives for clients in a multi-tenant platform. To schedule a demo of CYRISMA, please visit https://www.cyrisma.com/.
About Blueprint Equity
Blueprint Equity provides expansion capital to high-growth, capital-efficient enterprise software and technology-enabled services businesses worldwide. Blueprint has $275 million of assets under management and is based in La Jolla, CA. For more information, please visit www.onblueprint.com.
Media Contact:Oliver [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/cyrisma-a-leading-risk-management-platform-for-msps-secures-7-million-growth-equity-financing-led-by-blueprint-equity-302271854.html

ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufacture. Centivax is developing Cent-Flu, a universal influenza vaccine, consisting of a proprietary multivalent mixture of 22 unique mRNA transcripts delivered as a lipid nanoparticle (LNP) encapsulated mRNA vaccine. In vivo, the vaccine has been demonstrated to convey protection against current, past, and future influenza strains. BioCina will provide proven expertise in the selection of optimal plasmid manufacturing cell lines, Master Cell Bank (MCB) and plasmid manufacturing, to support Centivax’s progression to First-in-Human clinical trials.

 BioCina’s Chief Executive Officer, Mark W. Womack stated, “We’re privileged to support Centivax’s breakthrough approach to sustained flu prevention and we couldn’t be more excited to be their partner of choice to initiate cGMP manufacturing, thus advancing the journey to bring such an important vaccine to market. This is a tremendous opportunity for the BioCina Team to leverage our world-class capabilities in cell line development, cell banking, and cGMP plasmid production.”
Centivax’s Chief Executive Officer, Jacob Glanville, said, “We are thrilled to announce BioCina as our Master Cell Bank manufacturing partner for the first phase of manufacturing our universal influenza vaccine. BioCina’s exemplary expertise and track record in mRNA/LNP MCB, combined with their state-of-the-art facilities, aligns perfectly with Centivax’s commitment to innovation and quality. This partnership enables us to leverage BioCina’s expertise to ensure the highest standards of vaccine production. Together, we’re taking a significant step forward in bringing our universal influenza vaccine to market, with the goal of providing broad, lasting protection against the disease on a global scale.”
About BioCinaBioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA, TGA and Health Canada. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including the U.S., Europe, and the Asia Pacific. Australia offers one of the most attractive tax incentives globally (up to 48.5% cash refund), and one of the world’s premier trial networks, making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing products. Visit https://biocina.com.
About CentivaxCentivax is a universal vaccine platform technology company founded and led by experts in vaccinology, vaccine regulatory affairs, immunology, and computational bioengineering. The universal vaccine platform intellectual property has demonstrated unprecedented breadth of protection against influenza and coronaviruses. The platform delivers ultra-broad neutralizing titers, HAI titers and in-vivo protection in ferrets, pigs, rats, mice and human immune organoids. Development of the Centivax platform has been financially supported by the Global Health Investment Corporation (GHIC) BARDA venture arm, NFX, BLUE KNIGHT™ J&J/BARDA program, the Bill and Melinda Gates Foundation, the National Institute of Health (NIH), the Naval Medical Research Center, the Walter Reed Army Institute of Research, the Medical Technology Enterprise Consortium, the Department of Defense, and the National Institute for Innovation in Manufacturing Biopharmaceuticals. Centivax is on a mission to accelerate the world’s transition to a post-pathogen humanity.
Media [email protected] 
Photo – https://mma.prnewswire.com/media/2526553/BioCina_Centivax_partnership_image.jpg

View original content:https://www.prnewswire.co.uk/news-releases/centivax-selects-global-cdmo-biocina-to-initiate-cgmp-manufacturing-of-revolutionary-universal-influenza-vaccine-302271200.html